CLINICAL_TRIALS
trial_result
· 2010-07-26
Clinical Trial Update: Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients [Phase 4]
Summary
This Phase 4 study reports on the short-term efficacy of starting prednisone at 12.5 mg in patients with polymyalgia rheumatica.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Genova | Conditions: Polymyalgia Rheumatica | Phase 4 | Status: COMPLETED